Thelansis

Stiff-Person Syndrome (SPS) Market Outlook Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Stiff-Person Syndrome (SPS) Overview Stiff-person syndrome (SPS) is a rare, debilitating autoimmune CNS disorder characterised by progressive muscle rigidity, episodic painful spasms, and heightened sensitivity to external stimuli — noise, touch, and emotional stress — resulting from autoimmune disruption of GABAergic inhibitory neurotransmission within the spinal cord and brainstem. The pathophysiology is predominantl...

Stiff-Person Syndrome (SPS) Market Outlook Thelansis’s “ ⁠ Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 ”  covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ⁠ Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and...

Stiff-Person Syndrome (SPS) Market Outlook Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

  Stiff-Person Syndrome (SPS) Market Outlook Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Stiff-Person Syndrome (SPS) Overview Stiff person syndrome (SPS) encompasses a spectrum of disorders characterized by progressively increasing axial rigidity accompanied by intermittent, painful spasms. This condition predominantly affects females and may arise idiopathically or secondary to autoimmune disorders or paraneoplastic conditions, accounting for approximately 5% of cases. Variants within this syndrome include s...

  Stiff person syndrome (SPS) encompasses a spectrum of disorders characterized by progressively increasing axial rigidity accompanied by intermittent, painful spasms. This condition predominantly affects females and may arise idiopathically or secondary to autoimmune disorders or paraneoplastic conditions, accounting for approximately 5% of cases. Variants within this syndrome include stiff limb syndrome, jerking stiff person syndrome, and progressive encephalomyelitis with rigidity and myoclonus (PERM). The clinical course of SPS is variable, often ameliorating during sleep but exacerbating with movement, sensory stimuli, or emotional stress. Patients may also experience spasms and myoclonic jerks. In SPS, anti-glutamic acid decarboxylase (anti-GAD) autoantibodies are detected in 50–90% of cases, with other associated autoantibodies, including anti-amphiphysin and anti-glycine receptors. The presence of anti-GAD antibodies is predominantly linked to autoimmune diseases such as ...